关注公众号
收藏产品 产品详情
特异性（Specificity）
Specifically recognizes the target DM-1 & DM-4.
抗体来源（Source）
Monoclonal Anti-DM-4 Antibody, Rabbit IgG (M1H02) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.
克隆号（Clone）
M1H02
亚型（Isotype）
Rabbit IgG | Rabbit Kappa
偶联（Conjugate）
Unconjugated
免疫原（Immunogen）
DM-4-BSA
应用（Application）
ApplicationRecommended UsageELISA4-500 ng/mL纯化（Purification）
Protein A purified / Protein G purified
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
质量管理控制体系（QMS）
推荐产品
数据展示
活性（Bioactivity）-ELISA
Immobilized Monoclonal Anti-DM-4 Antibody, Rabbit IgG (M1H02) (Cat. No. DM4-MY2519a) at 1 μg/mL, add Tusamitamab Ravtansine in the 100% Human Serum and then add Biotinylated Human CEACAM-5, His,Avitag at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Serial dilutions of DM4 were added into Monoclonal Anti-DM-4 Antibody, Rabbit IgG (M1H02) (Cat. No. DM4-MY2519a): Tusamitamab Ravtansine binding reactions. The half maximal inhibitory concentration (IC50) is 0.06 μg/mL (Routinely tested).
Protocol
Immobilized Monoclonal Anti-DM-4 Antibody, Rabbit IgG (M1H02) (Cat. No. DM4-MY2519a) at 1 μg/mL (100 μL/well) can bind Tusamitamab Ravtansine with a linear range of 0.5-16 ng/mL (Routinely tested).
Protocol
交叉验证-Cross Verification
ELISA binding of Monoclonal Anti-DM-4 Antibody, Rabbit IgG (M1H02) (Cat. No. DM4-MY2519a) with Tusamitamab Ravtansine, Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), ADC-Duocarmycin and Trastuzumab MMAE conjugated antibody respectively.
The coating antibody was Monoclonal Anti-DM-4 Antibody, Rabbit IgG (M1H02) (Cat. No. DM4-MY2519a), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Tusamitamab Ravtansine, Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), ADC-Duocarmycin and Trastuzumab MMAE conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-DM-4 Antibody, Rabbit IgG (M1H02) (Cat. No. DM4-MY2519a) is specific to Tusamitamab Ravtansine, and has no cross-reactivity with Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), ADC-Duocarmycin and Trastuzumab MMAE (Routinely tested).
用户评价 发表评论
联系我们 
项目合作 